Zhenglufeng

Lufeng Zheng is an associate professor in the School of Life Science and Technology at China Pharmaceutical University. He completed his doctoral studies in Microbial and Biochemical Pharmacy and received his Ph.D. from China Pharmaceutical University in 2016. He is passionate about cancer metastasis, stemness, and drug resistance, and translating research into cancer prevention and control. Especially, he has twelve years of experience in breast cancer research, including breast cancer angiogenesis, apoptosis, ferroptosis, metastasis, stemness, and drug resistance and designing innovative studies. He has published over 45 peer-reviewed journal articles with h-index = 25.

1.Zheng L, Zhang Y, Mei S, Xie T, Zou Y, Wang Y, Jing H, Xu S, Dramou P, Xu Z, Li J, Zhou Y, Niu MM. Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer. J Med Chem. 2024 Apr 17. doi: 10.1021/acs.jmedchem.3c02433.

2.Gu X, Wei F, Tong J, Liu Y, Chen S, Zheng L*, Xing Y*. MiR-9 promotes G-MDSC recruitment and tumor proliferation by targeting SOCS3 in breast cancer. FASEB J. 2024 Jan;38(1):e23388.

3.Zheng L, Zou Y, Xie T, Wu X, Tan Y, Mei S, Geng Y, Chen S, Xu S, Niu MM. Discovery of a Dual Tubulin and Neuropilin-1 (NRP1) Inhibitor with Potent In Vivo Anti-Tumor Activity via Pharmacophore-based Docking Screening, Structure Optimization, and Biological Evaluation. J Med Chem. 2023 Dec 14;66(23):16187-16200.

4.Miao Z, Li J, Wang Y, Shi M, Gu X, Zhang X, Wei F, Tang X, Zheng L*, Xing Y*. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation. Mol Cancer. 2023 Dec 13;22(1):205.

5.Liu Y, Chen Y, Zhao Q, Xie T, Xiang C, Guo Q, Zhang W, Zhou Y, Yuan Y, Zhang Y, Xi T, Li X, Zheng L. A positive TGF-β/miR-9 regulatory loop promotes the expansion and activity of tumour-initiating cells in breast cancer. Br J Pharmacol. 2023 Apr 14.

6.Zhou M, Li J, Xu J, Zheng L, Xu S. Exploring human CYP4 enzymes: Physiological roles, function in diseases and focus on inhibitors. Drug Discov Today. 2023 May;28(5):103560.

7.Yuan Y, Yao H, Zhou M, Ma X, Zhou Y, Xu J, Niu M, Yin J, Zheng L*, Xu S*. Identification of a Novel Potent CYP4Z1 Inhibitor Attenuating the Stemness of Breast Cancer Cells through Lead Optimization. J Med Chem. 2022 Dec 8;65(23):15749-15769.

8.Yang Y, Lu Y, Zhang C, Guo Q, Zhang W, Wang T, Xia Z, Liu J, Cheng X, Xi T, Jiang F, Zheng L*. Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis. Cell Mol Life Sci. 2022 Jun 11;79(7):360.

9.Zheng L, Ren R, Sun X, Zou Y, Shi Y, Di B, Niu MM. Discovery of a Dual Tubulin and Poly(ADP-Ribose) Polymerase-1 Inhibitor by Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, and Biological Evaluation. J Med Chem. 2021 Nov 11;64(21):15702-15715.

10.Liu Y, Zhao Q, Xi T, Zheng L*, Li X*. MicroRNA-9 as a paradoxical but critical regulator of cancer metastasis: Implications in personalized medicine. Genes Dis. 2020 Oct 23;8(6):759-768.

11.Ni H, Qin H, Sun C, Liu Y, Ruan G, Guo Q, Xi T, Xing Y, Zheng L*. MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. Stem Cell Res Ther. 2021 Jun 5;12(1):325.

12.Xing Y, Ruan G, Ni H, Qin H, Chen S, Gu X, Shang J, Zhou Y, Tao X, Zheng L. Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression. Front Immunol. 2021 May 18;12:624725.

13.Liu H, Qin H, Zhou Y, Yuan Y, Liu Y, Chen Y, Yang Y, Ni H, Xi T*, Zheng L*. HET0016 attenuates the stemness of breast cancer cells through targeting CYP4Z1. Mol Carcinog. 2021 Jun;60(6):413-426.

14.Zhao Q, Liu Y, Wang T, Yang Y, Ni H, Liu H, Guo Q, Xi T*, Zheng L*. MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. Eur J Pharmacol. 2020 Oct 5;884:173359.

15.Guo Q, Wang T, Yang Y, Gao L, Zhao Q, Zhang W, Xi T*, Zheng L*. Transcriptional Factor Yin Yang 1 Promotes the Stemness of Breast Cancer Cells by Suppressing miR-873-5p Transcriptional Activity. Mol Ther Nucleic Acids. 2020 Sep 4;21:527-541.

16.Qin H, Ni H, Liu Y, Yuan Y, Xi T8, Li X*, Zheng L8. RNA-binding proteins in tumor progression. J Hematol Oncol. 2020 Jul 11;13(1):90.

17.Yang Y, Li X, Wang T, Guo Q, Xi T*, Zheng L*. Emerging agents that target signaling pathways in cancer stem cells. J Hematol Oncol. 2020 May 26;13(1):60.

Study the roles of CYP4Z1 in tumor progression and explore potential anti-cancer drugs.

Outstanding Young Backbone Teacher of Jiangsu Province Qinglan Project